Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

Fri, 17 Oct 2025 07:30:00 EST

Highlights include clinical data from Phase 3 studies in Community Acquired Pneumonia (CABP) and microbiologic data from a Phase 2 study in nontuberculous mycobacterial pulmonary disease (NTM-PD) caused by Mycobacterium abscessus complex (MABc), as well as additional clinical and non-clinical data from Company- and investigator-sponsored studies
Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Wed, 21 May 2025 08:26:00 EST

BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition...
Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference

Fri, 16 May 2025 07:30:00 EST
- First conference presentations for:
  Phase 2b study for nontuberculous mycobacterial pulmonary disease (NTM PD) caused by Mycobacterium abscessus complex (MABc)
  Phase 3 OPTIC-2 study in moderate-to-severe community-acquired bacterial pneumonia (CABP)
BOSTON, May 16, 2025 (GLOBE...
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

Thu, 10 Apr 2025 07:30:00 EST

Highlights will include data from non-clinical and real-world patient use
BOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company developing specialty therapies for community care and public health challenges, today announced that data from several new...
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Wed, 19 Mar 2025 21:25:00 EST
- Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 million patient market
- Acquisition advances Paratek's vision to become a multi-product company focused on...
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

Thu, 14 Nov 2024 09:00:00 EST

-- Onshoring of NUZYRA is a Key Deliverable in Company's Partnership with U.S. Biomedical Advanced Research and Development Authority (BARDA) to Enhance National Security
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical...

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

Fri, 08 Nov 2024 09:00:00 EST

First randomized placebo-controlled trial in NTM abscessus
Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms
Microbiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacycline
In this 12-week study,...

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

Mon, 14 Oct 2024 07:31:00 EST

-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA

BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that...

Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens

Wed, 31 Jul 2024 07:30:00 EST

- No Emergence of Resistance was Observed
- Additional Years of Surveillance are Under Way

BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital,...

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

Thu, 18 Jul 2024 07:30:00 EST

Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-Tolerated
Largest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last Decade
Label Update Discussions with FDA to Begin as Early...

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Thu, 18 Apr 2024 07:30:00 EST

BOSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, today announced that three new pre-clinical studies with NUZYRA^® (omadacycline) will be...

Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract

Tue, 05 Mar 2024 06:45:00 EST

Oral NUZYRA Tablets Procured by BARDA were Manufactured in the United States as Part of the Company's Onshoring Initiative
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories...

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China's National Reimbursement Drug List

Wed, 13 Dec 2023 08:53:00 EST

BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced that China's National Healthcare Security Administration (NHSA) has added the oral formulation of...

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

Thu, 05 Oct 2023 08:00:00 EST

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from...

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

Thu, 21 Sep 2023 08:58:00 EST

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital ("Gurnet Point") and Novo Holdings A/S ("Novo Holdings") announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and...

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

Mon, 18 Sep 2023 09:37:00 EST

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders...

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

Tue, 12 Sep 2023 07:30:00 EST

Follows the recommendation from ISS to vote FOR the transaction
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and...

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

Thu, 07 Sep 2023 15:34:00 EST

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional Shareholder...

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

Thu, 03 Aug 2023 08:00:00 EST

-- NUZYRA^® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022

--Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarter
...

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

Wed, 02 Aug 2023 17:36:00 EST

Transaction Provides Paratek Stockholders with Immediate Value and Liquidity

Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievement of a Commercial Milestone for a Total Potential Value of $3.00 per Share

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

Mon, 10 Jul 2023 08:00:00 EST

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones
-- Next procurement expected in early 2024

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the...

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

Tue, 27 Jun 2023 12:01:00 EST

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today acknowledged receipt of a letter from NexPoint Asset Management,...

European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Tue, 27 Jun 2023 08:00:00 EST

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that the European...

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023

Mon, 12 Jun 2023 08:00:00 EST

BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data...

Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings

Tue, 06 Jun 2023 09:05:00 EST

Transaction Provides Paratek Shareholders with Immediate Value and Liquidity

Reflects Potential Value of $3.00 per Share of Common Stock, Including Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 on Achievement of a Commercial Milestone

Total...

Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

Tue, 09 May 2023 16:05:00 EST

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $26.2 Million from the Core Commercial Business, a 32% Increase Over First Quarter 2022

-- Company Reiterates Full-Year Revenue Guidance of $143 to $158 Million

-- Announces Full-Year R&D and SG&A Expense Guidance...

Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9

Mon, 01 May 2023 08:30:00 EST

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.

The audio webcast can be accessed under "Events and Presentations" in the Investor Relations...

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023

Mon, 10 Apr 2023 07:30:00 EST

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data...

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

Thu, 16 Mar 2023 07:30:00 EST

-- NUZYRA^® (omadacycline) Generated Net U.S. Sales of $98.7 Million from the Core Commercial Business, a 45% Increase Over the Prior Year

-- Continued Progress on the Rare Disease Nontuberculous Mycobacteria (NTM) & BARDA Project BioShield Anthrax Programs

BOSTON, March ...

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16

Wed, 08 Mar 2023 08:30:00 EST

BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2022.

The audio webcast can be accessed...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Wed, 01 Mar 2023 16:05:00 EST

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on February 28, 2023,...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Wed, 01 Feb 2023 16:05:00 EST

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on January 31, 2023, the...

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)

Wed, 18 Jan 2023 07:00:00 EST

National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security...

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Thu, 05 Jan 2023 08:00:00 EST

Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022
Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in...

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

Tue, 20 Dec 2022 07:30:00 EST

BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company's independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022.

Dr. Stein was selected unanimously by the independent directors of the Board, in recognition...

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

Mon, 19 Dec 2022 07:30:00 EST

100% Survival Rate in Anthrax-infected Rabbits Treated with Omadacycline

Total Revenue Recognition to Paratek of $38.1 Million

BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) --...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Thu, 01 Dec 2022 17:45:00 EST

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on November...

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Mon, 21 Nov 2022 16:05:00 EST

BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that Evan Loh, M.D., chief...

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

Thu, 03 Nov 2022 16:05:00 EST

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021

-- Initiated Rabbit Pilot Efficacy Study for the Treatment of Pulmonary Anthrax

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Tue, 01 Nov 2022 16:05:00 EST

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on October 31, 2022, the...

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

Tue, 01 Nov 2022 08:00:00 EST

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, announces that Evan Loh, M.D., chief executive...

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Mon, 31 Oct 2022 08:00:00 EST

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the United States and Europe.

NUZYRA is the...

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

Tue, 25 Oct 2022 08:00:00 EST

BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022.

The audio webcast can be accessed under "Events and Presentations" in the Investor...

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

Thu, 13 Oct 2022 16:05:00 EST

Highlights include data from non-clinical and microbiology programs and real-world patient use

BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Mon, 03 Oct 2022 16:05:00 EST

BOSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on September 30, 2022,...

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Mon, 26 Sep 2022 08:30:00 EST

Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Paratek's Management Team
BOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for...

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Thu, 01 Sep 2022 16:05:00 EST

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on August 31, 2022, the...

Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Thu, 01 Sep 2022 08:00:00 EST

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Paratek President and...

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million

Wed, 03 Aug 2022 16:05:00 EST

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.1 Million from the Core Commercial Business, a 68% increase over Second Quarter 2021

-- Company Reiterates Full Year 2022 Financial Guidance

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:...

Paratek Pharmaceuticals News powered by B2i Technologies - SmartWire

Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies

Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024

Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of Inhalational Anthrax, Triggering Additional Procurement under BARDA Project BioShield Contract

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China's National Reimbursement Drug List

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S

Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S

Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings

Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million

Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings

Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax

Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter

European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023

Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings

Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million

Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9

Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023

Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)

Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference

Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract

Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3

Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million